The FINANCIAL — On September 2 Biogen announced that the Patent Trial and Appeal Board (PTAB) of the United States Patent and Trademark Office (USPTO) declined to institute an inter partes review of U.S. Patent 8,399,514, which covers the dosing regimen of daily administration of 480 mg of TECFIDERA (dimethyl fumarate).
TECFIDERA is the most prescribed oral treatment for multiple sclerosis (MS) globally, according to Biogen.
“TECFIDERA is a significant advance for the treatment of MS and this result speaks to the pioneering efforts by Biogen to bring this therapy to patients,” said George A. Scangos, Ph.D., chief executive officer of Biogen. “Patent protection is critical to enabling biopharmaceutical companies to develop new therapies and advance science and medicine.”
Discussion about this post